Advertisement

Drugs & Aging

, Volume 1, Issue 6, pp 431–439 | Cite as

Current Recommendations for the Prevention and Treatment of Influenza in the Older Population

  • Peter A. Gross
Review Article Drug Therapy

Summary

Influenza is a major cause of morbidity and mortality in the elderly. Influenza vaccine is recommended for people aged 65 years and older and those in long term care. Currently only 30% of high risk persons are vaccinated. Vaccination generally stimulates an adequate immune response, is well tolerated and is to be encouraged. Prophylactic amantadine 100 mg/day should be given for 2 weeks with influenza vaccine in the aged population when they have not been previously immunised. Broad application of these preventive measures would have a significant impact on reducing influenza prevalence in the elderly and other high risk groups.

Keywords

Influenza Influenza Virus Influenza Vaccine Amantadine Rimantadine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In Kendal AP & Patriarca PA (Eds) Options for the control of influenza, pp. 155–158, Alan R. Liss, New York, 1986Google Scholar
  2. Barker WM, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. American Journal of Epidemiology 112: 798–811, 1980PubMedGoogle Scholar
  3. Barker WM, Mullooly JP. Underestimation of the role of pneumonia and influenza in causing excess mortality. American Journal of Public Health 71: 643–645, 1981PubMedCrossRefGoogle Scholar
  4. Barker WM, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. In Kendal AP & Patriarca PA (Eds) Options for the control of influenza, pp. 169–182, Alan R. Liss, New York, 1986Google Scholar
  5. Belshe RB, Burk B, Newman F, Cerrute RL, Sim S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. Journal of Infectious Diseases 159: 430–4535, 1989PubMedCrossRefGoogle Scholar
  6. Beyer WEP, Palache AM, Baljet M, Masurel N. Antibody induced by influenza vaccines in the elderly: a review of the literature. Vaccine 7: 385–394, 1989PubMedCrossRefGoogle Scholar
  7. Buchner DM, Larson EB, White RF. Influenza vaccination in community elderly: a controlled trial of postcard reminders. Journal of the American Geriatric Society 35: 755–760, 1987Google Scholar
  8. Gate TR. Clinical manifestations and consequences of influenza. American Journal of Medicine 82(6A): 15–19, 1987Google Scholar
  9. Douglas Jr RG. Antimicrobial agents: antiviral agents. In Goodman and Gilman (Eds) The pharmacological basis of therapeutics, 8th ed., pp. 1182–1201, Pergamon Press, New York, 1990Google Scholar
  10. Fedson DS. Immunizations for health care workers and patients in hospitals. In Wenzel RP (Ed.) Prevention and control of nosocomial infections, pp. 116–174, Williams & Wilkins, Baltimore, 1987Google Scholar
  11. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978–1981. American Review of Respiratory Diseases 136: 550–555, 1987CrossRefGoogle Scholar
  12. Gomolin IH, Chapron DJ, Luhan PA. Lack of effect of influenza vaccine on theophylline levels and warfarin anticoagulation in the elderly. Journal of the American Geriatric Society 33: 269–272, 1985Google Scholar
  13. Grabowski N, May JJ, Pratt DS, Richtsmeier WJ, Bertino JS. The effect of split virus influenza vaccination on theophylline pharmacokinetics. American Review of Respiratory Diseases 131: 934–983, 1985Google Scholar
  14. Gross PA, Quinnan GV, Rodstein M, et al. Association of influenza immunization with reduction in mortality in an elderly population: a prospective study. Archives of Internal Medicine 148: 562–565, 1988aPubMedCrossRefGoogle Scholar
  15. Gross PA, Quinnan Jr GV, Weksler ME, Gaerlan PF, Denning CR. Immunization of elderly people with high doses of influenza vaccine. Journal of the American Geriatric Society 36: 209–212, 1988bGoogle Scholar
  16. Gross PA, Quinnan Jr GV, Weksler ME, Setia U, Douglas Jr RG. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 7: 303–308, 1989PubMedCrossRefGoogle Scholar
  17. Gross PA, Weksler ME, Quinnan Jr GV, Douglas Jr RG, Gaerlan PF, et al. Immunization of elderly people with two doses of influenza vaccine. Journal of Clinical Microbiology 25: 1763–1765, 1987PubMedGoogle Scholar
  18. Jann MW, Fidone GS. Effect of influenza vaccine on serum anticonvulsant concentrations. Clinical Pharmacy 5: 817–820, 1986PubMedGoogle Scholar
  19. Kendal AP. Epidemiologic implications of changes in the influenza virus genome. American Journal of Medicine 82(6A): 4–14, 1987PubMedCrossRefGoogle Scholar
  20. Lamb JR, McMichael AJ, Rothbard JB. T-cell recognition of influenza viral antigens. Human Immunobiology 19: 79–89, 1987CrossRefGoogle Scholar
  21. Liu KJ, Kendal AP. Impact of influenza epidemic on mortality in the United States from October 1972 to May 1985. American Journal of Public Health 77: 712–716, 1987CrossRefGoogle Scholar
  22. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. Journal of the American Medical Association 264: 1139–1141, 1990aPubMedCrossRefGoogle Scholar
  23. Margolis KL, Poland GA, Nichol RH, MacPherson DS, Meyer JD, et al. Frequency of adverse reactions after influenza vaccine. American Journal of Medicine 88: 27–30, 1990bPubMedCrossRefGoogle Scholar
  24. Meredith CG, Christian CD, Johnson RF, Troxell R, Davis GL, et al. Effects of influenza virus vaccine on hepatic drug metabolism. Clinical Pharmacology and Therapeutics 37: 396–401, 1985PubMedCrossRefGoogle Scholar
  25. Monto AS. Infleunza: quantifying morbidity and mortality. American Journal of Medicine 83(64); 20–25, 1987CrossRefGoogle Scholar
  26. Monto AS, Koopman JS, Longini Jr JM. Tecumsah study of illness. XIII: influenza infection and disease, 1976–1981. American Journal of Epidemiology 121: 811–822, 1985PubMedGoogle Scholar
  27. Nicholson KG. Influenza vaccination and the elderly. British Medical Journal 301; 617–618, 1990PubMedCrossRefGoogle Scholar
  28. Nicholson KG, Wiselka MJ. Amantadine for influenza A. British Medical Journal 302: 425–426, 1991PubMedCrossRefGoogle Scholar
  29. Perrotta DM, Decker M, Glezen WP. Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. American Journal of Epidemiology 122: 468–476, 1985PubMedGoogle Scholar
  30. Phair J, Kaufman CA, Bjoruson A, Adams L, Iinneman Jr C. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. Journal of Laboratory and Clinical Medicine 92: 882–888, 1978Google Scholar
  31. Recommendations of the Immunization Practices Advisory Committee (ACIP). Prevention and control of influenza. And addendum clarification. Morbidity and Mortality Weekly Report 39(RR-7): 1–15, 1990 Morbdity and Mortality Weekly Report 39: 469, 1990Google Scholar
  32. Reichelderfer PS, Kappus KD, Kendal AP. Economical laboratory support system for influenza virus surveillance. Journal of Clinical Microbiology 25: 947–948, 1987PubMedGoogle Scholar
  33. Ruben FL. Prevention and control of influenza: role of vaccine. American Journal of Medicine 82(6A): 31–34, 1987PubMedCrossRefGoogle Scholar
  34. Schoenbaum SC. Economic impact of influenza: the individual’s perspective. American Journal of Medicine 83(6A): 26–30, 1987CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Peter A. Gross
    • 1
    • 2
  1. 1.Department of Internal MedicineHackensack Medical CenterHackensackUSA
  2. 2.New Jersey Medical SchoolNewarkUSA

Personalised recommendations